Journal
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
Volume 94, Issue 7, Pages 779-787Publisher
CANADIAN SCIENCE PUBLISHING
DOI: 10.1139/cjpp-2016-0001
Keywords
piceatannol; HGF; hepatocytes; IL-10; cytokeratin-18
Categories
Ask authors/readers for more resources
Piceatannol is a polyphenolic analog of resveratrol that selectively inhibits the non-receptor tyrosine kinase-Syk. This study investigates the potential ability of piceatannol to attenuate liver fibrosis and protect hepatocytes from injury. Thioacetamide was injected in adult male mice (100 mg/kg, i.p., 3 times/week) for 8 weeks. Piceatannol (1 or 5 mg/kg per day) was administered by oral gavage during the last 4 weeks. Liver function biomarkers, tissue malondialdehyde (MDA), cytokeratin-18 (CK18), hepatocyte growth factor (HGF), and interleukin-10 (IL-10) were measured. Necroinflammation, fibrosis, expression of transforming growth factor (TGF)-beta(1), and alpha-smooth muscle actin (SMA) were scored by histopathological examination and immunohistochemistry. Obtained results showed ability of piceatannol (1 mg/kg) to restore liver function and reduce inflammation. It significantly (p < 0.001) reduced MDA, CK18, TGF-beta(1), and alpha-SMA expression, and increased HGF and IL-10. It can be concluded that piceatannol at low dose can inhibit TGF-beta(1) induced hepatocytes apoptosis and exerts an anti-inflammatory effect attenuating fibrosis progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available